. Author manuscript; available in PMC: 2021 Mar 5.

Published in final edited form as: Am J Ophthalmol. 2019 Jul 19;208:331–341. doi: 10.1016/j.ajo.2019.07.006

Table 4.

Sub-group analysis of all patients with follow-up > 4 years

BCVA at 4 years	Eyes belonging to Group I with SJS/TEN onset before January 2008 with more than 4 years of follow-up, n (%), n = 18 eyes of 9 patients	Eyes belonging to Group II with SJS/TEN onset after January 2008 with more than 4 years of follow-up, n (%), n = 22 eyes of 11 patients	P value
≥ 20/40	7/18 (39)^*	22/22 (100)^†	0.008
20/50 to 20/200	4/18 (22)^‡	0/22 (0)	0.2
< 20/200	7/18 (39)	0/22 (0)	0.026
< 20/200 to 20/400	2/18 (11)^§	0/22 (0)	0.48
CF	3/18 (17)	0/22 (0)	0.16
LP	2/18 (11)	0/22 (0)	0.48
NLP	0/18 (0)	0/22 (0)	1.00

SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis; BCVA = best-corrected visual acuity; CF = counting fingers; LP = light perception; NLP = no light perception

One eye with BCVA after undergoing Boston keratoprosthesis type 2

^†

Six eyes with BCVA with PROSE scleral lenses

^‡

One eye with BCVA after undergoing Boston keratoprosthesis type 1

^§

Both eyes with BCVA after undergoing tectonic penetrating keratoplasty